Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer

Resistance to TGF-β is frequently observed in ovarian cancer, and disrupted TGF-β/SMAD4 signaling results in aberrant expression of downstream target genes in the disease. Our previous study showed that ADAM19, a SMAD4 target gene, is down-regulated through epigenetic mechanisms in ovarian cancer wi...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Chou, Jian-Liang, Su, Her-Young, Chen, Lin-Yu, Liao, Yu-Ping, Hartman-Frey, Corinna, Lai, Yi-Hui, Yang, Hui-Wen, Deatherage, Daniel E., Kuo, Chieh-Ti, Huang, Yi-Wen, Yan, Pearlly S., Hsiao, Shu-Huei, Tai, Chien-Kuo, Lin, Huey-Jen L., Davuluri, Ramana V., Chao, Tai-Kuang, Nephew, Kenneth P., Huang, Tim H.-M., Lai, Hung-Cheng, Chan, Michael W.Y.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2010
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2829100/
https://ncbi.nlm.nih.gov/pubmed/20065949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/labinvest.2009.138
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים